Senior consultant, professor
Torben Frøstrup Hansen
Department of Oncology, Lillebaelt Hospital Vejle
Projekt styring | ||
Projekt status | Open | |
Data indsamlingsdatoer | ||
Start | 06.05.2022 | |
Slut | 31.07.2028 | |
Lung cancer is the leading cause of cancer related deaths. Early detection may improve the prognosis. Proteases and other proteins are aberrantly regulated in cancer patients and may therefore be useful for lung cancer detection. This prospective cohort study aims to investigate protease activity and other biomarkers for detecting lung cancer in patients referred for diagnostic work-up at the Department of Medicine, Vejle.
Lung cancer is the leading cause of cancer related deaths worldwide, partly because it is often detected in an advanced stage. The most feasible means of improving the mortality is earlier detection when the disease has not spread and cure is possible. Proteases are enzymes contributing to the regulation of the extracellular matrix. These enzymes show aberrant activity in cancer patients, and they may therefore be useful for lung cancer detection. Other proteins are also known to be abnormally regulated with a distinct pattern in cancer patients compared to healthy individuals. These patterns may be detectable by a novel method utilizing aptamers. Tumor cells shed DNA into the circulation, which may be detected by sensitive methods such as digital PCR. The aim of the study is to investigate the diagnostic sensitivity and specificity of a variety of biomarkers in subjects referred for lung cancer diagnostics: - Protease activity. - Aptamers. - Circulating tumor DNA.
Patients referred for diagnostic work-up on suspicion of lung cancer at the Fast-track outpatient clinic at the Department of Medicine, Lillebaelt Hospital Vejle
Data: Demographic and clinical data. Biological sample: Blood.
Department of Medicine, Lillebaelt Hospital Vejle
Department of Biochemistry and Immunology, Lillebaelt Hospital Vejle